A retrospective database analysis on persistence with inhaled corticosteroid therapy: comparison of two dry powder inhalers during asthma treatment in Germany.

Abstract

BACKGROUND:

Asthma is one of the most common chronic diseases worldwide. Patient persistence with treatment is essential to achieve sufficient outcomes, in particular to avoid exacerbations.

OBJECTIVE:

To investigate inhaled corticosteroid (ICS) therapy with two different inhalers (Novolizer® and Turbuhaler®) by comparing persistence, concomitant use of additional asthma medication and occurrence of exacerbations in real life.

STUDY DESIGN:

A retrospective analysis of prescription data from outpatient treatment was performed using the IMS Disease Analyzer. It provides longitudinal anonymized patient data from ~ 3,000 office-based physicians in Germany. Treatment persistence of asthma patients (ICD 10 code: J45) using 200 μg budesonide either via Novopulmon®/Budecort® (Novolizer group = NOV) or Pulmicort® (Turbuhaler group = TUR) was compared. Eligible patients hadthe first prescription of ICS medication (index day) between June 2001 and September 2007 and a data history available for at least twelve months before and after the index day.

RESULTS:

Analysis of 1,780 NOV and 664 TUR patients revealed that 1 year after index day, 89% NOV patients remained on their ICS compared to 85% TUR patients. NOV patients changed significantly less often and later to another ICS (p = 0.0108; log-rank test). Significantly fewer NOV patients switched temporarily or permanently to another ICS during the observation time (NOV group: 14.7%; TUR group: 20.8%; p = 0.0002, log-rank test). On average, NOV and TUR patients received comparable prescriptions of short acting medication (NOV more SABA, TUR more formoterol). There was a trend towards fewer prescriptions of systemic corticosteroids in NOV patients.

CONCLUSIONS:

Our results suggest better therapy persistence with NOV compared to TUR during asthma treatment in Germany. This can be a marker of better compliance and may contribute to prevent exacerbations. However, the number of exacerbations per patient year in the NOV group (0.12) compared to the TUR group (0.18) was not statically significantly lower (p = 0.4096).

• Authors: Thomas Voshaar, Karel Kostev, Juliana Rex, Detlef Schröder-Bernhardi, Joachim Maus, Ullrich Munzel
• Journal: International journal of clinical pharmacology and therapeutics (Int J Clin Pharmacol Ther) Vol. 50 Issue 4 Pg. 257-64 (Apr 2012) ISSN: 0946-1965 [Print] Germany
• PMID: 22456296 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Adrenal Cortex Hormones
• Anti-Asthmatic Agents
• Powders
• Budesonide

Topics

• Administration, Inhalation
• Adrenal Cortex Hormones (administration & dosage, adverse effects)
• Adult
• Aged
• Ambulatory Care
• Anti-Asthmatic Agents (administration & dosage, adverse effects)
• Asthma (drug therapy, physiopathology)
• Budesonide (administration & dosage, adverse effects)
• Chi-Square Distribution
• Databases as Topic
• Dry Powder Inhalers
• Female
• Germany
• Humans
• Kaplan-Meier Estimate
• Linear Models
• Logistic Models
• Lung (drug effects, physiopathology)
• Male
• Middle Aged
• Powders
• Proportional Hazards Models
• Retrospective Studies
• Time Factors
• Treatment Outcome
• Young Adult